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Background: To assess the tolerance of patients with small cell lung cancer undergoing
chemoradiation with tomotherapy-based image-guided radiotherapy (IGRT).
Materials and Methods: A retrospective review of the toxicity profile for nine patients
with small cell lung cancer of the limited stage who underwent chemoradiation delivered
with helical tomotherapy (HT) has been conducted.
Results: Acute grade 3–4 hematologic and esophagitis toxicities developed in two and
three patients respectively. One patient developed a pulmonary embolism during radio-
therapy. Seven patients had weight loss ranging from 0 to 30 pounds (median: 4 pounds).
Three patients had treatment breaks ranging from 2 to 12 days. At a median follow-up of
11 months (range: 2–24 months), no patients developed any radiation related toxicities such
as grade 3–4 pneumonitis or other long-term complications.The median survival was esti-
mated to be 15 months. There were two local recurrences, three mediastinal recurrences,
and six distant metastases.
Conclusion: Grade 3–4 toxicities remained significant during chemoradiation when radi-
ation was delivered with tomotherapy-based IGRT. However, the absence of grade 3–4
pneumonitis is promising and the use of HT needs to be investigated in future prospective
studies.
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INTRODUCTION
Standard of care for small cell lung cancer of limited stage is
concurrent chemotherapy and radiotherapy (1–7). Radiotherapy
usually starts within 30 days of the initiation of chemotherapy
to ensure an optimal outcome (5). Treatment toxicity of the
combined modality is significant because of the volume of the
normal organs irradiated (esophagus and lungs) and the bone
marrow suppression from chemotherapy. Grade 3–4 esophagitis,
pneumonitis, and hematologic toxicity occurred frequently (1–7).
Although there are still controversies about the technique of radi-
ation delivery and the most optimal dose of radiotherapy, most
institutions treated the gross tumor and mediastinum, which is
followed by a cone down to the gross tumor with the three-
dimensional conformal radiotherapy technique (3-D CRT). Some
institutions choose to treat the gross tumor and involved lymph
nodes only to decrease normal tissue toxicity with the risk of recur-
rence in the non-irradiated mediastinal lymph nodes (4). Recently,
new techniques of radiotherapy such as image-guided radiother-
apy (IGRT) has been introduced to help reduce the treatment
margins used to create the planning target volume through more
precise image guidance. This potentially decreases normal tissue
toxicity through reducing the volume of normal tissue included in
the high dose volume. It also allows improved tumor coverage and
the delivery of higher radiation to the target volume which poten-
tially improves loco-regional control without increasing the risk of
normal tissue complications. Preliminary results of IGRT in head
and neck and gastrointestinal cancers have been promising because
of significant sparing of normal organs at risk for radiotherapy
complications (8–12). This has prompted us to conduct this ret-
rospective study on the feasibility of delivering IGRT with helical
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tomotherapy (HT) in the setting of concurrent chemoradiation
for limited-stage small cell lung cancers.
MATERIALS AND METHODS
The medical records of nine patients with limited-stage small cell
lung cancers who underwent concurrent chemoradiation deliv-
ered with HT between September 2009 and February 2012 were
retrospectively reviewed. The University of Arizona Institutional
Review Board (IRB) approved the study and waived the require-
ment for patient consent because of the retrospective nature of the
study. All but one patient underwent platinum-based chemother-
apy with cisplatinum and etoposide (7) or carboplatin and etopo-
side (1). One patient refused chemotherapy because of the fear
of treatment-related toxicities. All patients had mediastinal nodal
involvement (8 N2, 1 N3) at presentation. Six patients had stage
IIIA and three patients had stage IIIB disease. Table 1 summarizes
patient characteristics. All patients underwent positron emission
tomography (PET) with computed tomography (CT) as part of
the staging. The PET-CT was also incorporated into the planning
CT to outline the target volume. All patients underwent simulation
and treatment in the supine position with their arms raised above
their heads and were immobilized using a custom-made Vac-Lok
cradle (Medtec, Orange City, IA, USA). For the actual simulation,
a CT scan of the chest with and without intravenous (IV) con-
trast was performed in the treatment position. The thorax area
from the neck to mid-abdomen was scanned with a slice thickness
of 3 mm. The CT scan without contrast was used for planning
to avoid possible interference of the contrast density on radio-
therapy isodose distribution. The gross tumor volume (GTV) was
defined as the post-chemotherapy tumor volume after one cycle of
chemotherapy. All patients underwent 4D simulation at the time
of the CT simulation to outline the tumor internal target volume
(ITV). Respiratory motion was accounted for by 4D CT which
retrospectively sums of the CT images collected from evenly sep-
arated time points (10 phases) throughout one breathing cycle.
The clinical target volume (CTV) was created by expansion of the
ITV, PET positive mediastinal lymph nodes, ipsilateral hilum, and
mediastinum with a 0.8 cm margin. For tumor located in the upper
lobes (8), the ipsilateral supraclavicular lymph node area was also
treated prophylactically and the lower mediastinum was excluded.
For tumor located in the lower lobe, the lower mediastinum was
treated but the supraclavicular lymph node area was excluded.
A margin of approximately 0.2 cm was added to create the final
PTV. The PTV and ITV was treated to a total dose of 4500 cGy
in 180 cGy/fraction and 5000 cGy in 200 cGy/fraction respectively.
All target volumes were checked daily before each treatment and
the isodose lines verified to ensure that no excessive radiation was
delivered to the OARs. Patients were simulated and re-planned
at 4000 cGy to account for tumor shrinkage, and/or expansion
of the lungs from resolution of the atelectasis. The residual gross
tumor ITV was boosted for an additional dose of 1000 cGy in
200 cGy/fraction (6) or 1500 cGy in 125 cGy/fraction twice a day
(bid) (3) to achieve a tumor dose of 6000–6500 cGy. The bid frac-
tionation was chosen when the tumor encased the blood vessels to
decrease the risk of hemorrhage as the tumor may already invade
into the adventitia of the blood vessels. Dose constraints for nor-
mal organs at risk for complications were the following: lungs
Table 1 | Patient characteristics.
Patient number 9
Median age 60 (46–84)
Sex
Female 2
Male 7
Histology Small cell
T stage
T1 4
T2 3
T4 2
N stage
N2 8
N3 1
Stage
IIIA 6
IIIB 3
Tumor location
RUL 4
LUL 3
RML 1
LLL 1
Follow-up 2–24 months (median: 11 months)
RUL: right upper lobe; LUL: left upper lobe; RML: right middle lobe; LLL: left
lower lobe.
(V20 <30%, V5 <50%); spinal cord: Dmax <40 Gy; cardiac ven-
tricles: V40<10%, V20<50%). Minimal target coverage was 95%
for all targets with at least 99% of the prescribed dose delivered
to the gross tumor and mediastinal lymph nodes. Radiotherapy
started on the second cycle of chemotherapy. Weekly complete
blood count (CBC) and blood chemistry to assess renal function
were performed during chemoradiation.
Treatment breaks and weight loss were recorded during
chemoradiation. Acute and long-term toxicities were graded
according to Radiotherapy Oncology Group (RTOG) group sever-
ity scale (http://ctep.cancer.gov). All patients had a follow-up
visit 1 month and regularly 3 months following treatment. Clinical
examination was performed at each follow-up to detect recurrent
disease and possible complications resulting from the treatment.
Patients were asked specifically about their exercise tolerance, dys-
phagia, weight loss, and difficulty to breathe compared to their
pre-treatment baseline. The patients were also monitored during
and following treatment with a team of dietitians because of the
expected grade 3–4 esophagitis. A PET-CT scan was performed
4, 10 months, and yearly after treatment if there was no clini-
cal evidence of disease. Patient with a complete response (CR)
on PET-CT will undergo prophylactic cranial irradiation (PCI).
Survival data was analyzed using Kaplan–Meier estimation.
RESULTS
PTV target coverage ranged from 96 to 98% (median: 97%). Max-
imum spinal cord dose ranged from 3300 to 4100 cGy (median:
3500 cGy). V20 and V5 for both lungs combined ranged from 6 to
25% (median: 22%) and 30 to 67% (median: 53%) respectively.
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Table 2 |Treatment toxicity.
Weight loss 0–30 pounds (median: 4 pounds
Treatment break Three patients had treatment breaks ranging from
2 to 12 days
Grade 3–4 toxicities
Hematologic 2/9 (22%)
Esophagitis 3/9 (30%)
Pulmonary embolism 1/9 (11%)
Because of the tumor location in the upper lobes in eight patients,
the cardiac ventricles doses were insignificant. Except for one
patient, all patients had significant shrinkage of the GTV dur-
ing treatment (30% or more of the pre-treatment tumor volume).
For one patient, tumor size increased during treatment and he
developed loco-regional failure later.
Two patients (22%) developed grade 3–4 hematologic toxi-
city. Three patients (33%) had grade 3–4 esophagitis and one
patient (11%) had pulmonary embolism. Median weight loss was
4 pounds (range: 0–30 pounds). Three patients (33%) had treat-
ment breaks ranging from 2 to 12 days (Table 2). Four patients
(44%) had a CR on PET-CT post treatment. However, only one
patient with a CR underwent PCI. The other three declined PCI
because of the fear of late neurotoxicity. Two of these patients
developed multiple brain metastases later and died. Two patients
developed local recurrences (22%) and three patients had medi-
astinal recurrences (33%). Six patients (66%) developed distant
metastasis (brain: 2, liver: 2, bones: 2, adrenals: 1). At a median
follow-up of 11 months (range: 2–24 months), the median and 2-
year survival was estimated to be 15 months and 28% respectively.
No patients developed grade 3–4 acute or late pneumonitis. The
acute esophagitis resolved by 6 weeks following treatment comple-
tion and all patients recovered from their weight loss. No patient
noticed a change of their breathing pattern or physical activity
compared the pre-treatment baseline.
DISCUSSION
Randomized studies of small cell lung cancer with limited stages
revealed poor survival with a high rate of loco-regional recur-
rences and distant metastases (2, 6, 13–17). Radiation therapy
dose ranged from 4500 cGy in 150 cGy bid to 4500–5000 cGy in 25
daily fractions. Despite a low dose of radiation, patients still expe-
rienced grade 3–4 pneumonitis ranging from 3.2 to 6.2% (2, 13,
15, 16). In severe cases death may occur (2, 13, 15). Among long-
term survivors, grade 3–4 pulmonary fibrosis has been reported
in 37–39% of the patients (17). Radiation-induced lung injury
was most likely due to irradiation of a large volume of the nor-
mal lungs with the conventional radiotherapy technique when the
ipsilateral mediastinum was included in the treatment volume.
Preliminary data indicated that by limiting the target volume to
the GTV and adjacent lymph nodes, radiation dose escalation was
feasible to improve local control. With this approach, Bogard et al.
reported that the GTV dose may be increased to 7000 cGy with
grade 3 pneumonitis observed in only 5% of the patients (18).
Thus, a new radiation technique that allows radiation dose escala-
tion without increasing lung toxicity may potentially improve local
control and survival while preserving patient quality of life. The
introduction of intensity-modulated radiotherapy (IMRT) may
allow for decrease normal tissue toxicity because of the rapid dose
fall-off away from the target volume (19). However, when IMRT
was used for elective nodal irradiation in patients with limited-
stage small cell lung cancer, 7% of the patients still experienced
grade 3 pneumonitis despite the fact that two-third of the patients
was treated to 4500 cGy in 30 bid fractions and the target was
limited to the GTV and lymph nodes involved on PET scan (20).
Thus, our study is the first to demonstrate the feasibility of adaptive
IGRT delivered with HT-based image to spare the normal lungs
from excessive irradiation as the GTV was treated to a higher dose
of radiation (6000–6500 cGy) and the ipsilateral mediastinum was
included in the treatment field. The absence of grade 3–4 pneu-
monitis and long-term lung injury in our study may be attributed
to multiple factors. We outlined the GTV post-chemotherapy as
a target volume as Hu et al. (3) observed no difference in local
control if the post-chemotherapy GTV was treated instead of the
pre-chemotherapy GTV. As the tumor shrinks during radiother-
apy, re-planning and boosting to the residual tumor may allow for
sparing of the normal lungs without compromise of target cover-
age (21). All but one of the patients had significant decreased in
size of the tumor which is in agreement with other studies. Hugo
et al (22) reported that the GTV volume decreased by 23% after
5 weeks of radiotherapy in patients with non-small cell lung can-
cer. In addition, compared to conventional IMRT, HT provides
comparable target coverage with a significant reduction of the
lungs V20 (23). We also set high priority to limit the V5 for nor-
mal lung as the patients received concurrent chemotherapy which
may increase radiosensitization of the normal lungs and the risks
of severe pneumonitis (23). The low V5 and V20 in our study
indicated that the normal lungs may be preserved from excessive
irradiation with HT-based IGRT in the treatment of patients with
small cell lung cancer of limited stage. This is true even if elec-
tive nodal irradiation is administered. Thus, dose escalation to
the gross disease with reduced margins may be feasible with HT-
based IGRT. This hypothesis warrants further validation in future
prospective trials with larger number of patients.
We do observe a high rate of grade 3–4 esophagitis which is
unavoidable because the esophagus is included in the ipsilateral
mediastinum. However, all patients recovered following treatment
and resumed a normal physical activity. The addition of a radia-
tion protector such as amifostine may be an option to decrease the
severity of esophagitis and improve patient quality of life during
treatment (24).
The study is limited by the fact that it only includes a small
number of patients and a short follow-up after treatment. Thus,
it can only serve as a preliminary report which warrant further
validation in future prospective studies.
CONCLUSION
Image-guided radiotherapy delivered with HT may potentially
reduce the risk of radiation related severe toxicities, and espe-
cially lung toxicities in the setting of concurrent chemoradiation
for limited-stage small cell lung cancer. This may allow for fur-
ther radiation dose escalation to the gross tumor to improve
treatment outcome. Prospective studies with a large number of
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patients should be conducted in the future to further validate this
hypothesis.
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